Department of Surgery, Indiana University School of Medicine, Indianapolis, IN.
Department of Medicine, Division of Gastroenterology, Indiana University Hospital, Indianapolis, IN.
J Am Coll Surg. 2014 Jul;219(1):122-9. doi: 10.1016/j.jamcollsurg.2014.03.021. Epub 2014 Mar 19.
Although the natural history of intraductal papillary mucinous neoplasm (IPMN) remains unclear, large surgical series have reported malignancy in 40% to 90% of main pancreatic duct (MPD)-involved IPMN. Accordingly, the 2012 International Consensus Guidelines recommend surgical resection in patients with suspected MPD involvement. We hypothesized that nonoperative management of select patients with suspected MPD-involved IPMN might be indicated.
From 1992 to 2012, 362 patients underwent surgical resection for pathologically confirmed IPMN at a single academic center. A retrospective review of prospectively collected data was performed. Main pancreatic duct involvement was suspected with an MPD diameter ≥5 mm on preoperative imaging. A multivariate analysis was conducted to assess predictors of malignancy.
Of 362 patients, 334 had complete data for analysis. Main pancreatic duct involvement was suspected preoperatively in 171 patients. Final pathology revealed 20% high-grade dysplastic and 27% invasive IPMN (47% malignant). Preoperative cytopathology and serum carbohydrate antigen 19-9 independently predicted malignancy (p = 0.003 and p = 0.002, respectively) and invasiveness (p < 0.0001 and p = 0.001, respectively). Patients with both negative preoperative cytopathology and normal serum carbohydrate antigen 19-9 (ie, double negatives) had a lower rate of malignancy and invasiveness (28% and 8% vs 58% and 38%; p < 0.0001). The MPD diameter did not predict malignancy or invasiveness (p = 0.36 and p = 0.46, respectively).
Patients with suspected MPD-involved IPMN have a highly variable rate of malignancy. Despite recent International Consensus Guidelines recommendations, these data suggest that MPD diameter is not an optimal gauge of malignant risk. Nonoperative management of suspected MPD-involved IPMN in select patients, particularly double negatives, might be indicated. Depending on age and comorbidity, operative risk might outweigh the risk of malignant progression in these patients.
尽管胰管内乳头状黏液性肿瘤(IPMN)的自然病程仍不清楚,但大量的外科系列研究报告称,主胰管(MPD)受累的 IPMN 中有 40%至 90%为恶性。因此,2012 年国际共识指南建议对疑似 MPD 受累的患者进行手术切除。我们假设,选择性地对疑似 MPD 受累的 IPMN 患者进行非手术治疗可能是合适的。
从 1992 年到 2012 年,在一家学术中心,362 例经病理证实的 IPMN 患者接受了手术切除。对前瞻性收集的数据进行了回顾性分析。术前影像学检查显示 MPD 直径≥5mm 时怀疑有 MPD 受累。进行了多变量分析以评估恶性肿瘤的预测因素。
在 362 例患者中,有 334 例患者有完整的数据进行分析。术前怀疑 171 例患者存在 MPD 受累。最终病理显示 20%为高级别异型增生,27%为浸润性 IPMN(47%为恶性)。术前细胞学和血清碳水化合物抗原 19-9 独立预测恶性肿瘤(p=0.003 和 p=0.002)和侵袭性(p<0.0001 和 p=0.001)。术前细胞学和血清碳水化合物抗原 19-9 均为阴性(即双阴性)的患者恶性肿瘤和侵袭性发生率较低(分别为 28%和 8%,58%和 38%;p<0.0001)。MPD 直径不能预测恶性肿瘤或侵袭性(p=0.36 和 p=0.46)。
疑似 MPD 受累的 IPMN 患者的恶性肿瘤发生率差异很大。尽管最近的国际共识指南建议,但这些数据表明,MPD 直径不是恶性风险的最佳指标。在某些患者中,特别是双阴性患者,可能需要对疑似 MPD 受累的 IPMN 进行非手术治疗。根据年龄和合并症,这些患者的手术风险可能超过恶性进展的风险。